Drug Trial Radar · NCT05822245
A Study of PER-001 in Participants With Open-Angle Glaucoma
Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
May 25, 2023
Primary completion
Apr 20, 2025
Study completion Apr 20, 2025
Sponsor
- Lead sponsor
- Perfuse Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
Conditions
- Open-angle Glaucoma
Interventions
PER-001 Intravitreal Implant - Low DoseDrug
PER-001 Low Dose Intravitreal Implant
PER-001 Intravitreal Implant - High DoseDrug
PER-001 High Dose Intravitreal Implant
PER-001 Intravitreal Implant - ShamDrug
PER-001 Intravitreal Sham
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Measurement for Safety - Change from Baseline at Week 24 using Best-corrected Visual Acuity (BCVA)Time frame: End of Study(Week 24)
- Ocular Measurement for Safety - Change from Baseline at Week 24 using BiomicroscopyTime frame: End of Study(Week 24)
- Ocular Measurement for Safety - Change from Baseline at Week 24 using Intraocular Pressure (IOP)Time frame: End of Study(Week 24)
- Ocular Measurement and Implant Assessment for Safety - Change from Baseline at Week 24 using Dilated OphthalmoscopyTime frame: End of Study(Week 24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Perfuse Therapeutics, Inc.
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.